Posted by AGORACOM
at 11:25 AM on Monday, February 22nd, 2021
LAS VEGAS and VANCOUVER, British Columbia, Feb. 22, 2021 (GLOBE NEWSWIRE) — TAAT ™ LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “TAAT ™ ”) is pleased to announce that more than CAD $100,000 worth of TAAT™ Original, Smooth, and Menthol has been ordered this weekend, following the launch of the Company’s online storefront on Wednesday, February 17, 2021.
Based on early-stage performance, the Company continues its promotional efforts to attract smokers aged 21+ to the TAAT™ online store, including a campaign of targeted integrated banners in online content (commonly known as “native advertisements”) as well as a digital out-of-home campaign on thousands of Ohio gasoline pump displays.
To offer smokers aged 21+ who are trying TAAT™ for the first time the option to sample individual packs of TAAT™ without the need to purchase a full carton, the Company has added a Taste Explorer Bundle to its online store. This bundle consists of one 20-stick pack of each of the three TAAT™ varieties; Original, Smooth, and Menthol .
The Company’s TryTAAT promotion remains active, in which smokers aged 21+ in eligible 1 states can request a complimentary sample pack of the TAAT™ variety of their choice.
This promotion as well as its terms and conditions can be accessed at the following link: http://trytaat.com/free-pack/
Posted by AGORACOM-JC
at 10:52 AM on Monday, February 22nd, 2021
Announced today that Mr. P. Peter Pascali, CEO and Chair of PyroGenesis, has been invited to present at the prestigious 7 th Annual Gabelli & Company Waste Services Symposium being held virtually on Thursday, March 18th. Mr. Pascali will be presenting at 1:45pm ET.
MONTREAL, Feb. 22, 2021 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQB: PYRNF) (FRA: 8PY), (the “Company”, the “Corporation” or “PyroGenesis”) a Company that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to announce today that Mr. P. Peter Pascali, CEO and Chair of PyroGenesis, has been invited to present at the prestigious 7 th Annual Gabelli & Company Waste Services Symposium being held virtually on Thursday, March 18th. Mr. Pascali will be presenting at 1:45pm ET.
“It is indeed an honor to be asked again to present at this distinguished conference,” said Mr. P. Peter Pascali, CEO & Chair of PyroGenesis. “I look forward to the event, and presenting to both existing and prospective investors, as well as to members of the environmental services industry.”
Posted by AGORACOM
at 10:37 AM on Monday, February 22nd, 2021
GameOn is planning to list in Q1 2021.
It recently strategically beefed up its Board and Advisory Council, bringing on noted sports, entertainment, gaming and wagering execs
GameOn will be the next Victory Square portfolio company going public, following FansUnite Entertainment Inc.
VANCOUVER, British Columbia, Feb. 22, 2021 — Victory Square Technologies Inc. (“ Victory Square ”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased to announce that its portfolio company GameOn Entertainment Technologies Inc. (“ GameOn ”) has launched a non-brokered private placement of up to 4,285,715 subscription receipts of GameOn (each a “ Subscription Receipt ”) for aggregate gross proceeds of up to CAD$1,500,000 at a price of CAD$0.35 per Subscription Receipt (the “ SR Offering ”).
The Subscription Receipts will be issued pursuant to and governed by a subscription receipt agreement to be entered between GameOn and an escrow agent to be appointed by GameOn on or prior to the closing date of the SR Offering (the “ SR Agreement ”).
In accordance with the SR Agreement, each Subscription Receipt shall be automatically converted without any further action on the part of the holder thereof into one unit of GameOn (each, a “ SR Unit ”) upon the satisfaction of certain escrow release conditions (the “ Escrow Release Conditions ”) including the receipt of conditional approval by GameOn with respect to the listing of the common shares of GameOn (“ GameOn Shares ”) on the Canadian Securities Exchange (the “ CSE ”) and the receipt of a final prospectus in the Province of British Columbia in connection with the final prospectus of GameOn.
Posted by AGORACOM-JC
at 10:35 AM on Monday, February 22nd, 2021
Announces the results of the Special Meeting (the “Meeting”) held virtually on Friday February 19, 2021.
Authorization from the Company’s shareholders to enable the Board of Directors, within its sole discretion, to consolidate the Company’s issued and outstanding common shares on the basis of one post-consolidation common share for a number of pre-consolidation common shares ranging between two (2) and fourteen (14) as outlined in the Company’s management information circular and voting material sent to the shareholders.
TORONTO, Feb. 22, 2021 – POET Technologies Inc. (“ POET ” or the “ Company ”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets announces the results of the Special Meeting (the “Meeting”) held virtually on Friday February 19, 2021.
The Company’s Chairman and Chief Executive Officer, Dr. Suresh Venkatesan, conducted the formal business of the Meeting, which focused solely on seeking authorization from the Company’s shareholders to enable the Board of Directors, within its sole discretion, to consolidate the Company’s issued and outstanding common shares on the basis of one post-consolidation common share for a number of pre-consolidation common shares ranging between two (2) and fourteen (14) as outlined in the Company’s management information circular and voting material sent to the shareholders.
Posted by AGORACOM-JC
at 10:21 AM on Monday, February 22nd, 2021
Announce that it has established its previously announced scientific advisory board, (see press release dated January 20th, 2021) to assist the Company to accelerate existing applications and to develop new BioCloud technology applications.
“Now more than ever viral detection technology is critical to getting the economy and everyday life back to normal,” says Paul Ghezzi, CEO of Kontrol.
TORONTO, ON / February 22, 2021 /Kontrol Technologies Corp.(CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol Technologies” or “Kontrol” or “Company“) is pleased to announce that it has established its previously announced scientific advisory board, (see press release dated January 20th, 2021) to assist the Company to accelerate existing applications and to develop new BioCloud technology applications.
“Now more than ever viral detection technology is critical to getting the economy and everyday life back to normal,” says Paul Ghezzi, CEO of Kontrol. “Vaccines are integral to a broader recovery, however more technology is required for detection and monitoring. We are pleased to be taking a leadership role in this new industry of real-time viral detection infrastructure. Our technology was developed for the current pandemic and the pandemics of the future.”
“We are very pleased to establish a world class advisory board for Kontrol BioCloud,” says Gary Saunders, VP Kontrol. “Our advisory board members are at the top of their field and their counsel will be very important to the future of Kontrol BioCloud and other innovative applications of the technology we may seek to develop.”
Posted by AGORACOM-JC
at 9:53 AM on Monday, February 22nd, 2021
Else has developed a breakthrough, proprietary process to further ensure the safety of the formula.
This patent pending process will contribute greatly to Else’s realization of an infant formula in worldwide markets and provide higher standards of safety, health and natural nutrition for babies, toddlers and children.
VANCOUVER, BC , Feb. 22, 2021 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (“Else” or the “Company”) the plant-based baby, toddler and children nutrition company , announces as part of its progress towards commercializing a clean label, dairy-free and soy-free, plant-based infant formula, Else has developed a breakthrough, proprietary process to further ensure the safety of the formula. This patent pending process will contribute greatly to Else’s realization of an infant formula in worldwide markets and provide higher standards of safety, health and natural nutrition for babies, toddlers and children.
This new process builds on the company’s already clean and most natural production process that ensures the highest quality standards – it does not use harsh chemicals or detergents (commonly used in the industry) and does not impact the formula’s amino acids or other macronutrients.
“The World Health Organization considers the first 1000 days of life as critically important to long term health and wellness. It’s the window of time where optimum brain and immune system development is established. Infant formula is the exclusive form of nourishment for many babies during this critical period of development. The recent consumer and regulatory call to action is especially prudent to the formula category. Else Nutrition is voluntarily and proactively changing the way they source ingredients, manufacture their products, and think about food safety all in an effort to optimize environmental and public health now and into the future,” said Jaclyn Bowen MPH, MS food and consumer products safety and systems engineer and Executive Director of Clean Label Project.
“We’re leading a clean revolution, disrupting the baby food industry by setting a new standard in quality, transparency and sustainability. This latest development brings us even closer to bringing clean label, plant-based, minimally processed infant formula to wanting parents worldwide,” said Hamutal Yitzhak , CEO and Co-Founder of Else Nutrition.
The novel pre-process was under development for nearly a year. A full Pilot stage was successfully completed and tested recently at the company’s innovation center in Northern Israel , positively demonstrating reduction of specific elements levels.
Already a recipient of The Clean Label Project’s Purity Award (an honor only bestowed after products are tested for over 400 contaminants and heavy metals and meet the organization’s highest standard) for its Plant-Based Complete Nutrition for Toddlers product, Else continues its commitment to ‘cleaning up’ the baby/toddler nutrition aisles with safe, clean label products of the highest quality.
Else is proud to share this exciting development and its continued commitment to baby food safety and quality, in light of a recent congressional report that revealed that many baby food products offered by leading manufacturers contain significant levels of toxic heavy metals.
Else’s ‘Beyond Organic’ Processing
Else Nutrition is primarily made of almonds, tapioca and buckwheat; three core ingredients that go through a clean, all-natural process that provides the protein, carbohydrates, and fat directly from the whole plants, along with phytonutrients, fiber, vitamins and minerals nature intended to provide optimal nourishment for children. Else is free of dairy, soy and corn-syrup, and is made with non-GMO ingredients. It is made using a clean, most natural and sustainable industry process.
Posted by AGORACOM-JC
at 9:45 AM on Monday, February 22nd, 2021
Now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States.
The Company’s common shares are traded on the OTCQB under the symbol “IDKFF”.
TORONTO, Feb. 22, 2021 — ThreeD Capital Inc. (the “Company” or “ThreeD”) (CSE:IDK) (OTCQB:IDKFF) is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States. The Company’s common shares are traded on the OTCQB under the symbol “IDKFF”.
DTC is a subsidiary of the Depository Trust and Clearing Corporation, a United States company that manages the electronic clearing and settlement of publicly traded companies. DTC services reduces costs and accelerates the settlement process for investors and brokers trading Canadian securities in the United States.
Sheldon Inwentash, CEO of ThreeD commented, “We are thrilled with obtaining DTC eligibility, as it represents an important step forward in increasing liquidity, broadening our shareholder base and building a strong presence for the Company within the US capital markets sphere.”
About ThreeD Capital Inc.
ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors. ThreeD’s investment strategy is to invest in multiple private and public companies across a variety of sectors globally. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services and access to the Company’s ecosystem.
For further information:
Jakson Inwentash Vice President Investments [email protected] Phone: 416-941-8900 ext 107
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
Posted by AGORACOM
at 9:29 AM on Monday, February 22nd, 2021
Testing South African COVID-19 variant with the Company’s new solubilized Ivermectin technology.
Mutation is now the most dominant form of the COVID-19 virus in South Africa
Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that it will be testing the new B.1.351 South African COVID-19 variant in its upcoming Bio Safety Level 4 (“BSL-4”) lab study, which is analyzing viral clearance efficacy with the Company’s new solubilized Ivermectin technology.
According to the World Health Organization*, the mutated B.1.351 COVID-19 variant is now the most dominant form of the COVID-19 virus in South Africa and is believed to be more infectious and thus easier to spread. As the COVID-19 virus continually mutates, researchers are assessing the impact of the current vaccines that are in distribution to understand if they may be rendered less effective or even noneffective**.
“We felt it was critical to look at this new South African COVID-19 variant given the immediate complexities we are seeing with the pace of vaccine rollout and the high probability that current vaccines will not be as effective, if at all, against these emerging mutations,” stated Dennis Hancock, President and CEO of Mountain Valley MD. “It is important to us across our broad human health objectives that our solubilized Ivermectin technology can be confidently applied as the broadest COVID-19 therapeutic and number one choice in the world when a vaccine falls short.”
The Company has previously communicated that it believes its solubilized Ivermectin would be suitable for a broad therapeutic across a wide range of viruses in the future, not just limited to COVID-19.
“It is not clear if the current vaccines will protect you from the new variants and early information is that vaccines are not as effective on the mutations. We are attempting in our work with the BSL-4 lab to target novel COVID-19 variants that would prove Ivermectin’s broad activity in interfering with the replication of the virus and thus broadly applies across multiple variants versus being specific to a variant the way a vaccine would be,” stated Mike Farber, Director of Life Sciences at MVMD.
As communicated in the Company’s news release on January 27, 2021, the BSL-4 trial will be the first of its kind ever conducted with human grade solubilized Ivermectin anywhere in the world and its design was led by the Company’s key scientific advisor, Dr. John Clements. Dr. Clements is Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine and has over 35 years of experience in vaccine, immunology and infectious diseases research and development, with a distinguished scientific career focused on developing and evaluating vaccines for a wide range of infectious diseases globally.
Posted by AGORACOM
at 9:14 AM on Monday, February 22nd, 2021
Initial tests on lithium-ion batteries successful in the recovery of lithium, nickel and cobalt found as a coating on aluminium foil in the core of the batteries.
Leached more than 99% of the cobalt and of the nickel contained in the batteries.
St-Georges Eco-Mining Corp. (CSE:SX) (OTC:SXOOF) (FSE: 85G1) (CNSX:SX.CN) is pleased to disclose that its initial tests conducted on an array of lithium-ion batteries have been successful in confirming that the selective leach, conducted with its proprietary blend of acids, allows for the recovery of the lithium, nickel and cobalt that are found as a coating on aluminium foil in the core of the batteries.
The Company’s metallurgical team was able to leach more than 99% of the cobalt and of the nickel contained in the batteries. Furthermore, the aluminium foil used to hold the different metals in the batteries’ core remains intact and can be recycled.
Company scientists are comfortable that the results obtained on these metals are repeatable and should scale. Initial lithium test results have been in line with expectations and require additional tests at scale prior to disclosure. These additional tests are ongoing, and results are expected sometime in March.
Fig. 1 The metals in solution, to the left the lithium / cobalt circuit, to the right the nickel copper circuit.
For testing, batteries were dismantled at the Company’s contracted pilot plant facility, CIMMS, under the supervision of qualified chemists and metallurgists. Enrico Di Cesare, St-Georges VP Research & Development, established the protocol and supervised the process. The batteries were dismantled manually, and the cores were immersed in St-Georges’ proprietary leach solution for 30 minutes. The Company expects to optimize and reduce this exposure duration with the aim of bringing it closer to the 5 min leach time required by the Nevada clays. Aluminium was taken out of the solution in its solid form and set aside. No test for residues was conducted on the aluminium in the preliminary tests. Metals were then targeted for recuperation in solution. The powders obtained were tested on-site and sent for independent testing by CIMMS
Posted by AGORACOM
at 9:01 AM on Monday, February 22nd, 2021
Engineering studies to identify and define various value add options for the development of the Cañariaco Project.
First goal is to define/identify a smaller, higher grade, start up option for Cañariaco with a smaller CapEx and accelerated payback period
Candente Copper Corp. (TSX:DNT, BVL:DNT) (“Candente Copper”, “Company”) is pleased to announce that it has received and is reviewing proposals from two internationally acclaimed engineering firms for engineering studies to identify and define various value add options for the development of the Cañariaco Project.
The first goal of the engineering study is to define/identify a smaller, higher grade, start up option for Cañariaco with a smaller initial capital expenditure (“CapEx”) and accelerated payback period. This is expected to be able to be permitted and financed to production more quickly than the larger option. The intention would be that once the development capital is paid back, the smaller operation could then be expanded to fully recognize the value of the large copper-gold resource that exists at Cañariaco.
The second goal is to explore other potential options with a mind to establish both cost efficiencies and environmental, social and governance (“ESG”) friendly development options. Current industry wide ESG initiatives and responsible investing is driving innovation in environmentally friendly, sustainable development and finance products. This innovation has been accelerated by the COVID-19 pandemic and increased urgency around the 17 UN Sustainable Development Goals, resulting in many new development options to consider now.
